EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis

Lyndon P James iD, Fayette Klaassen iD, Sedona Sweeney iD, Jennifer Furin iD, Molly F Franke iD, Reza Yaesoubi iD, Dumitru Chesov, Nelly Ciobanu iD, Alexandru Codreanu iD, Valeriu Crudu iD, Ted Cohen iD, Nicolas A Menzies iD

PLOS Medicine · 2024

DOI: 10.1371/journal.pmed.1004401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Medicine, 2024. Verfasst von Lyndon P James und 11 weiteren Autor:innen. Beteiligte Einrichtung: PhD Program in Health Policy, Harvard University, Cambridge, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Rifampin, Tuberculosis, Multidrug-Resistant, Quality-Adjusted Life Years. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Emerging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment (EOT) outcomes to longer regimens. We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) to a standard of care strategy using a 9- or 18-month regimen depending on whether fluoroquinolone resistance (FQ-R) was detected on drug susceptibility testing (DST). Methods and findings The primary objective was to determine whether 6 months of BPaLM is a cost-effective treatment strategy for RR-TB. We used genomic and demographic data to parameterize a mathematical model estimating long-term health outcomes measured in quality-adjusted life years (QALYs) and lifetime costs in 2022 USD ($) for each treatment strategy for patients 15 years and older diagnosed with pulmonary RR-TB in Moldova, a country with a high burden of TB drug resistance. For each individual, we simulated the natural history of TB and associated treatment outcomes, as well as the process of acquiring resistance to each of 12 anti-TB drugs. Compared to the standard of care, 6 months of BPaLM was cost-effective. This strategy was estimated to reduce lifetime costs by $3,366 (95% UI: [1,465, 5,742] p < 0.001) per individual, with a nonsignificant change in QALYs (−0.06; 95% UI: [−0.49, 0.03] p = 0.790). For those stopping moxifloxacin under the BPaLM regimen, continuing with BPaL plus clofazimine (BPaLC) provided more QALYs at lower cost than continuing with BPaL alone. Strategies based on 6 months of BPaLM had at least a 93% chance of being cost-effective, so long as BPaLC was continued in the event of stopping moxifloxacin. BPaLM for 6 months also reduced the average time spent with TB resistant to amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin, and pyrazinamide, while it increased the average time spent with TB resistant to delamanid and pretomanid. Sensitivity analyses showed 6 months of BPaLM to be cost-effective across a broad range of values for the relative effectiveness of BPaLM, and the proportion of the cohort with FQ-R. Compared to the standard of care, 6 months of BPaLM would be expected to save Moldova’s national TB program budget $7.1 million (95% UI: [1.3 million, 15.4 million] p = 0.002) over the 5-year period from implementation. Our analysis did not account for all possible interactions between specific drugs with regard to treatment outcomes, resistance acquisition, or the consequences of specific types of severe adverse events, nor did we model how the intervention may affect TB transmission dynamics.

Conclusions

Compared to standard of care, longer regimens, the implementation of the 6-month BPaLM regimen could improve the cost-effectiveness of care for individuals diagnosed with RR-TB, particularly in settings with a high burden of drug-resistant TB. Further research may be warranted to explore the impact and cost-effectiveness of shorter RR-TB regimens across settings with varied drug-resistant TB burdens and national income levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisRifampinTuberculosis, Multidrug-ResistantQuality-Adjusted Life YearsAntitubercular AgentsMoxifloxacinHumansMoldovaAdultMaleFemaleModels, TheoreticalDrug Therapy, CombinationLinezolidDiarylquinolinesMiddle AgedTreatment OutcomeDrug Administration ScheduleAdolescentMycobacterium tuberculosis

Substanzen

RifampinAntitubercular AgentsMoxifloxacinLinezolidDiarylquinolinesbedaquiline

Autor:innen und Institutionen

  • PhD Program in Health Policy, Harvard University, Cambridge, Massachusetts, United States of America.
  • Center for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America.
  • Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America.
  • Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
  • Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, United States of America.

ORCID-Profile: Lyndon P James, Fayette Klaassen, Sedona Sweeney, Jennifer Furin, Molly F Franke, Reza Yaesoubi, Nelly Ciobanu, Alexandru Codreanu, Valeriu Crudu, Ted Cohen, Nicolas A Menzies

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

James, L. P., Klaassen, F., Sweeney, S., Furin, J., Franke, M. F., Yaesoubi, R., Chesov, D., Ciobanu, N., Codreanu, A., Crudu, V., Cohen, T., & Menzies, N. A. (2024). Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004401

Vancouver

James LP, Klaassen F, Sweeney S, Furin J, Franke MF, Yaesoubi R, et al. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine. 2024. doi:10.1371/journal.pmed.1004401

BibTeX
@article{James2024,
  author = {James, Lyndon P and Klaassen, Fayette and Sweeney, Sedona and Furin, Jennifer and Franke, Molly F and Yaesoubi, Reza and Chesov, Dumitru and Ciobanu, Nelly and Codreanu, Alexandru and Crudu, Valeriu and Cohen, Ted and Menzies, Nicolas A},
  title = {Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis},
  journal = {PLOS Medicine},
  year = {2024},
  doi = {10.1371/journal.pmed.1004401}
}
Kostenlos starten →